Thyroid Hormone Replacement: DTE, T4/T3 Options, and Transition Considerations for Providers

By Andrea Daniels, PharmD, Vice President of Clinical Services

What Providers Need to Know About Thyroid Hormone Replacement

The regulatory picture for desiccated thyroid extract (DTE) may be changing, but the clinical question remains familiar: How do you protect continuity of care while choosing a thyroid hormone replacement plan that is appropriate for the individual patient?

The answer is not a universal conversion table. It begins by viewing the individual patient. Confirming the diagnosis, identifying the exact DTE product and dose being taken, understanding why a change is being considered, and developing a documented plan for monitoring and follow-up. The goal is to support an individualized transition based on the patient’s clinical circumstances rather than relying on a one-size-fits-all conversion.

Not all thyroid medications have FDA approval status or the same clinical evidence. These differences should be considered when evaluating medication options.

What Has the FDA Said About Desiccated Thyroid Extract?

Desiccated thyroid extract, or DTE, is an animal-derived thyroid medication typically prepared from porcine thyroid glands. It contains both thyroxine (T4) and triiodothyronine (T3) and is sometimes described as “natural thyroid.” That consumer-facing term can obscure an important distinction: DTE is an animal-derived, manufactured or compounded prescription product, not a dietary supplement.

DTE products have appeared in U.S. thyroid care under several familiar names, including Armour ThyroidⓇ, NP ThyroidⓇ, and Nature-Throid. These products are often discussed together because they are animal-derived thyroid products rather than synthetic levothyroxine or liothyronine-only medications. Providers should distinguish longstanding clinical use from current FDA approval status.

The FDA states that currently marketed animal-derived thyroid products are not FDA-approved. The FDA also classifies them as biological products under the Public Health Service Act and says they are not eligible for traditional compounding pathways.1

In an August 6, 2025, notice, the FDA said it intended to allow time for patients to transition to an FDA-approved thyroid hormone replacement product while continuing a risk-based enforcement approach.2 On March 11, 2026, FDA said it planned to publish draft guidance before August 2026 describing its compliance priorities and possible conditions for continued enforcement discretion involving marketed unapproved animal-derived thyroid products.3

That language did not establish an automatic stop-dispensing date. At this time, the FDA has not provided a definitive discontinuation date for these products.1

The FDA’s notices were directed to manufacturers, importers, and distributors. They did not announce a patient-specific prescribing or pharmacy-dispensing cutoff, although changes in the FDA’s enforcement priorities could affect product supply.

The Alliance for Pharmacy Compounding (APC) has filed a citizen petition asking the FDA to reconsider its classification and establish a pathway that preserves access to compounded DTE. A pending petition does not change the FDA’s current position, but it is relevant context for providers following the issue.4

What this means in practice

Providers should avoid telling patients either that DTE will automatically disappear in August 2026 or that access will remain unchanged. Neither conclusion is supported by the FDA’s current communication.

An accurate message is:

The FDA’s current position creates regulatory uncertainty around animal-derived thyroid products. No discontinuation date has been announced, but product availability and enforcement priorities may change after the FDA issues additional guidance.

Continuity planning is reasonable. A rushed or formula-driven medication change is not.

What Does Desiccated Thyroid Extract Contain?

The hormone content and T4-to-T3 ratio of desiccated thyroid extract (DTE) differ from those of endogenous human thyroid hormone secretion. Porcine DTE has an approximate T4-to-T3 ratio of 4.2:1, compared with an estimated human thyroid-secretion ratio of approximately 14:1. T3 concentrations can fluctuate after administration, so the timing of the dose and laboratory draw can meaningfully affect interpretation.6,8

Product-specific labeling also matters. For example, Armour ThyroidⓇ labeling identifies one grain as 60 mg containing 38 mcg of T4 and 9 mcg of T3.⁵ These values should not be generalized to every DTE product without confirming the manufacturer, labeled grain strength, and stated hormone content.

Clinical findings should also be considered alongside laboratory results. Possible signs of excessive thyroid hormone exposure include palpitations, tachycardia, tremor, nervousness, insomnia, heat intolerance, increased bowel frequency, or unexplained weight loss.⁷ These findings should prompt clinical and laboratory reassessment, rather than an assumption that the patient simply needs additional time to adjust.

Most importantly, the labeled T4 and T3 content of DTE does not create a one-to-one clinical equivalence with a levothyroxine dose or a compounded T4/T3 prescription. Product content is one input. The patient’s diagnosis, age, comorbidities, laboratory findings, current thyroid status, and medication history remain central to the transition plan.

Why Levothyroxine Remains the Standard Thyroid Hormone Replacement Medication

Levothyroxine supplies synthetic T4, which has a long half-life and is converted in peripheral tissues to T3. Professional guidelines continue to identify levothyroxine alone as the standard medication for most patients with primary hypothyroidism.6

Consistent administration is essential before concluding that the medication or dose is inadequate. Current levothyroxine labeling directs patients to take it once daily on an empty stomach, 30 to 60 minutes before breakfast, and at least four hours apart from medications known to interfere with absorption. Regular administration near certain foods may also require reassessment.7

Before Adjusting a Dose or Adding T3, Verify:

• The original biochemical diagnosis and whether the patient has primary or central hypothyroidism
• The exact product, strength, and dosing schedule
• Adherence and consistency of administration
• Timing relative to food, calcium, iron, antacids, bile-acid sequestrants, and other potential interactions
• Gastrointestinal conditions or procedures that may affect absorption
• Use of biotin, which may interfere with thyroid laboratory assays
• Other possible contributors to fatigue, cognitive complaints, weight change, or mood symptoms

Depending on the clinical presentation, those competing contributors may include anemia or documented nutrient deficiency, sleep apnea, depression or anxiety, menopause, medication effects, chronic illness, or another autoimmune condition.8,10

Persistent symptoms deserve attention, but they do not establish a need for T3. Differences in peripheral thyroid-hormone metabolism have been proposed as one explanation for persistent symptoms, but no validated clinical marker currently identifies patients who will predictably be appropriate candidates for T3-containing medication.8,10

For providers, that distinction is practical, not semantic. “Thyroid optimization” should not be shorthand for adding T3 or targeting a single laboratory value. In a provider setting, it should mean confirming the patient’s circumstances and a possible diagnosis, improving administration consistency, addressing competing factors, avoiding under- or over-replacement, and monitoring the patient over time.

When to Consider a Monitored T4/T3 Combination Medication Trial

Randomized studies of T4/T3 combination medication have produced inconsistent findings, and major guidelines do not recommend it for routine use. The 2023 British Thyroid Association and Society for Endocrinology (BTA/SfE) consensus describes a narrower framework in which a monitored trial may be considered.8

That framework includes:

• A substantiated diagnosis of overt primary hypothyroidism
• An adequate trial of appropriately administered levothyroxine
• A levothyroxine dose optimized using clinical assessment and biochemical monitoring
• Persistent symptoms that remain meaningful to the patient
• Evaluation for relevant comorbidities and nonthyroid causes
• Detectable TSH within the reference range before liothyronine is introduced
• Defined care goals and a plan for reassessment
• Clinician experience or specialist involvement appropriate to the patient’s circumstances

A previous thyroidectomy does not independently establish a need for liothyronine. Neither does a patient’s preference to preserve T3 from a prior DTE regimen. Those factors may be part of shared patient-provider decision-making, but they do not replace the clinical selection criteria.

There is also no validated “poor converter” test that predicts who will respond to T3. Genetic variants and differences in deiodinase activity remain areas of study, not routine prescribing tools.8,10

When a T4/T3 trial is selected, the BTA/SfE consensus recommends maintaining TSH within the reference range and allowing approximately three to six months before determining whether predefined goals have been met.8 If those goals are not met, the rationale for continuing liothyronine should be reconsidered.

Laboratory Timing Matters with Liothyronine

T3 concentrations can vary substantially based on when liothyronine was taken. The laboratory request and clinical record should document:

• That the patient is taking liothyronine
• The formulation and dosing frequency
• The time of the most recent dose
• The time of the blood draw

For serial monitoring, using a consistent relationship between the dose and blood draw makes trends easier to interpret. A free T3 value without dose-timing context can be misleading.What Compounded Thyroid Medication Can—and Cannot—Individualize

Life isn’t one-size-fits-all. Neither is medicine. But personalization does not make a formulation clinically equivalent nor equivalent under FDA requirements.

When permitted under applicable law and supported by a valid patient-specific prescription, compounding may allow a prescriber to address a documented need such as:

• A patient-specific strength that is not commercially available
• A specified, individualized T4-to-T3 ratio
• Exclusion of a dye or other excipient that is problematic for the individual patient
• A dosage form needed because an available commercial product cannot meet the patient’s documented clinical need

Compounding does not establish:

• FDA review or approval
• Equivalence to an FDA-approved product
• Transfer of clinical data from commercial levothyroxine or liothyronine products
• A predictable clinical response (individual experiences may vary)
• A universal DTE conversion
• Product-specific in vivo release or pharmacokinetic performance

A compounded formulation may be prepared using modified-release excipients. Product-specific in vivo release, pharmacokinetic performance, or any clinical study results from an FDA-approved product do not apply. Without formulation-specific data, the medication should not be described as supporting stable T3 concentrations throughout the day.

Under the FDA’s current position, animal-derived thyroid products are biological products and may not be eligible for traditional compounding pathways.1 That is separate from patient-specific prescriptions prepared with synthetic levothyroxine and liothyronine, which remain subject to applicable federal and state compounding requirements.

The pharmacist’s role is to provide factual information about ingredients, available strengths, dosage forms, preparation considerations, and the patient-specific prescription. The prescriber retains responsibility for clinical appropriateness, diagnosis, medication selection, dosing, monitoring, and follow-up.

DTE Transition Checklist for Thyroid Medication Changes

A thyroid medication transition should be treated as a clinical reassessment, not a calculation exercise.

1. Confirm the current medication regimen

Document the manufacturer, product name, labeled strength, grain designation, tablet count, total daily dose, dose timing, duration of use, and any recent supply or formulation changes. “One grain” is not enough information to support a transition plan.

2. Confirm the indication and baseline

Review the original clinical indication and diagnosis when available, current TSH and free T4, prior laboratory trends, relevant symptoms, and the reason a change is being considered. If the patient takes T3-containing medication, interpret free T3 in the context of dose timing.

For central hypothyroidism, TSH is not a reliable measure of replacement adequacy. Monitoring should be guided by free T4 and the broader clinical picture.7

3. Review administration and absorption

Ask how the patient takes the medication, not merely whether the patient takes it. Food, supplements, interacting medications, inconsistent timing, malabsorption, and product switching can all change thyroid laboratory findings.

4. Identify transition precautions

Before adjusting the medication regimen, document pregnancy or pregnancy plans, suspected or known adrenal insufficiency, cardiovascular disease, arrhythmia history, age-related considerations, and osteoporosis or accelerated bone-loss risk.

5. Select the replacement strategy

For most adults with primary hypothyroidism, levothyroxine remains the clinical baseline. A selected T4/T3 trial may be considered only after the criteria above have been addressed.

Avoid presenting a DTE-to-levothyroxine or DTE-to-T4/T3 calculation as an exact conversion. Any starting regimen and transition pace require the prescriber’s independent judgment based on the individual patient.

6. Define monitoring before the change

Document the planned laboratory interval, symptom or quality-of-life measures, heart rate or rhythm considerations, possible signs of excessive or insufficient exposure, and the conditions under which the plan will be adjusted.

For adults with primary hypothyroidism, current levothyroxine labeling recommends checking TSH six to eight weeks after a dose change. Once a patient is stable, clinical and biochemical review is generally performed every six to twelve months and when clinical status changes.7

Monitoring and Follow-Up After a Thyroid Medication Change

A clear follow-up plan is one of the most valuable parts of any thyroid medication transition.

For primary hypothyroidism, monitoring commonly includes:

• TSH after an appropriate interval following a dose or formulation change
• Free T4 when clinically indicated or when TSH is outside the reference range
• Free T3 only when its use will inform care, interpreted in relation to liothyronine dose timing
• Heart rate, rhythm, and relevant cardiovascular symptoms
• Possible signs of excessive or insufficient thyroid hormone exposure
• The specific symptom or quality-of-life goals documented before the change
• Product, formulation, administration, and adherence changes since the prior assessment

If liothyronine is included, a suppressed TSH, new palpitations, tremor, insomnia, heat intolerance, or other possible signs of excessive exposure should prompt reassessment. Long-term continuation should be based on a documented, sustained individual response and ongoing monitoring, not simply on the fact that T3 was part of the previous regimen.

Thyroid Medication Precautions: Pregnancy, Adrenal, Cardiovascular, and Skeletal Considerations

Thyroid hormone replacement has a narrow therapeutic index. Individualization must include the circumstances in which under- or over-replacement carries additional risk.

Pregnancy

Levothyroxine is the recommended thyroid hormone replacement medication during pregnancy. The American Thyroid Association does not recommend starting or continuing DTE or T3-containing preparations during pregnancy because maternal T4 is important for fetal development.9

Pregnancy may increase levothyroxine requirements, and monitoring intervals are shorter. A patient who is pregnant, planning pregnancy, or undergoing fertility care should have a pregnancy-specific plan rather than a routine DTE transition.

Adrenal Insufficiency

Uncorrected adrenal insufficiency is a contraindication to levothyroxine. Introducing thyroid hormone before glucocorticoid replacement in a patient with adrenal insufficiency may trigger an adrenal crisis.7 When the history or presentation raises concern for adrenal insufficiency, adrenal evaluation should occur before a thyroid medication change.

Cardiovascular Disease

Excessive thyroid hormone exposure may precipitate angina or arrhythmias, particularly in older adults and patients with underlying cardiovascular disease. Current levothyroxine labeling recommends beginning below the full replacement dose and titrating cautiously in patients at risk for atrial fibrillation or with cardiac disease.7

Skeletal Risk

Thyroid hormone over-replacement may increase bone resorption and decrease bone mineral density, with particular concern in postmenopausal patients. Avoiding chronically suppressed TSH and reassessing the ongoing need for T3-containing medication are important parts of follow-up.7,8

Thyroid hormones are not indicated for obesity or weight loss in euthyroid patients (meaning having a normally functioning thyroid gland with healthy levels of thyroid hormones). Weight change should not be used as the sole measure of whether a thyroid regimen is suitable.

Personalized Thyroid Hormone Replacement Requires Clinical Precision

The regulatory path for DTE may continue to change. The clinical principles should remain steady:

• Confirm the diagnosis
• Verify the exact medication and how it is taken
• Use levothyroxine as the clinical baseline for most patients
• Reserve T4/T3 combination medication for selected, monitored circumstances
• Avoid formulaic conversion claims
• Document risks, goals, laboratory timing, and follow-up before making the change

The future of medicine is personal. In thyroid care, personal should never mean improvised. It should mean clinically justified, clearly documented, and carefully monitored.

Strive pharmacists are available to provide formulation-specific information for valid, patient-specific prescriptions and to collaborate with providers within the boundaries of independent clinical judgment and applicable compounding requirements.

Watch the Strive Session: Navigate Modern Thyroid Care with Confidence

For a guided discussion of this evolving landscape, join me, Andrea Daniels, PharmD, as I review thyroid medication options, current regulatory considerations, transition planning, and whole-person factors that may inform provider-patient conversations.

This webinar is designed for:

• Functional and integrative medicine providers
• Primary care physicians and advanced practice providers
• Healthcare professionals managing patients with thyroid disorders
• Providers interested in personalized medicine and compounded medications

Topics covered include:

• The current thyroid medication options, including levothyroxine, and selected T4/T3 combination approaches
• Recent FDA communications affecting animal-derived thyroid products
• Patient-specific factors to consider when reviewing a medication regimen or planning a medication transition
• Monitoring, follow-up, and whole-person considerations that may shape thyroid care discussions

Watch the full Strive Session below.

Frequently Asked Questions About Thyroid Hormone Replacement

Is desiccated thyroid extract (DTE) FDA-approved?

The FDA states that currently marketed animal-derived thyroid products are not FDA-approved. FDA also considers them biological products that are ineligible for traditional compounding pathways. Strive Pharmacy is awaiting additional FDA guidance and clarification regarding the compounding of DTE.

What is synthetic thyroid hormone replacement?

Synthetic thyroid hormone replacement generally refers to levothyroxine, which supplies T4, and liothyronine, which supplies T3. Levothyroxine remains the standard medication for most patients with primary hypothyroidism. Liothyronine may be considered as part of a selected, monitored combination trial rather than routine use. Strive compounds with synthetic T4 and T3 ingredients.

How do natural desiccated thyroid and synthetic thyroid hormones differ?

“Natural thyroid hormone replacement” commonly refers to animal-derived DTE, which contains T4 and T3 in a fixed porcine ratio. Synthetic thyroid hormones include levothyroxine, which supplies T4, and liothyronine, which supplies T3. “Natural” does not mean unprocessed, FDA-approved, or suitable for every patient. Providers should use the product name, manufacturer, labeled strength, and T4/T3 content when documenting the regimen.

Can DTE be converted directly to levothyroxine or a T4/T3 combination?

Product content can inform the prescriber, but a mathematical comparison should not be presented as exact clinical equivalence. The transition plan should reflect the patient’s current thyroid status, age, comorbidities, laboratory findings, dosing history, and follow-up plan.

What should providers watch for when thyroid hormone exposure may be too high?

Possible signs include palpitations, tachycardia, tremor, nervousness, insomnia, heat intolerance, increased bowel frequency, and unexplained weight loss. Laboratory reassessment and review of dose timing, formulation, and administration are appropriate when these occur.

Become a Partner with Strive

Ready to become a Strive provider? The way you deliver care shapes everything—including how we work together. Choose the path that fits your practice.

In-Person Practice

For clinics, medical spas, and private practices that see patients in person and want a pharmacy partner built around their practice experience.

• Physical clinic, private practice, or medical spa
• In-person patient care
• Local or multi-location practice
• Looking for a true pharmacy partner

Start Here

Also offer telehealth appointments? You’re in the right place.

National Telehealth Platform

For virtual-first providers who need pharmacy infrastructure designed for the pace and reach of remote care.

• Virtual-first platform or company
• Remote prescribing across multiple states
• High patient volume without in-person visits
• Looking for scalable pharmacy infrastructure

Start Here

Don’t See Your Partnership Here?

Not every partnership fits a template—and that’s fine by us. We work with technology platforms, GPOs, virtual provider networks, pharmacies, and organizations across the healthcare landscape. Connect with our team so we can help identify the right path.

Start Here

Disclaimer:

This information is intended for educational purposes only and does not constitute medical advice. Refer to the cited references for more information regarding the content presented. The creators of this content disclaim any liability for decisions made based on the information presented. The information provided relates to patient-specific compounding. Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, have not been reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. Prescribers should use their independent clinical judgment when determining appropriateness for individual patients.